City of Hope

NIH awards City of Hope $2.2M grant

Thursday, November 5, 2015

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor. The grant, awarded to Defu Zeng, M.D., a professor of diabetes immunology and hematopoietic cell transplantation at the Beckman Research Institute of City of Hope, will be used by researchers to study the interactions of immune cells known as T cells and B cells during the development of GVHD.

[Read More]

Coronado Biosciences, City of Hope form Mustang Therapeutics

Friday, March 20, 2015

Coronado Biosciences has formed a new company, Mustang Therapeutics, in partnership with California research and treatment center City of Hope. Mustang initially will focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.

[Read More]

Amgen submits BLA for investigational BiTE immunotherapy blinatumomab

Thursday, September 25, 2014

Amgen has submitted a Biologics License Application (BLA) to the FDA seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow.

[Read More]

City of Hope finds potential cure for type 1 diabetes

Friday, May 18, 2012

City of Hope, a research, treatment and education center for cancer, diabetes and other life-threatening diseases based in Duarte, Calif., has developed a combination therapy to treat late-stage type 1 diabetes (T1D) that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study was published in the May 9, 2012, edition of Science Translational Medicine.

[Read More]